Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Telix Reports Fourth Quarter 2022 Financial Results 2023-01-18 08:50
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update 2023-01-09 06:37
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances 2022-12-22 06:04
Telix Announces Executive Leadership Appointments 2022-12-05 06:39
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand 2022-11-22 20:00
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy 2022-11-22 04:59
Telix Acquires Optimal Tracers 2022-11-14 06:36
Telix to Present at Jefferies London Healthcare Conference 2022 2022-11-11 20:00
Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study 2022-11-07 06:48
Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022 2022-10-27 10:23
Telix and UniQuest to Collaborate on Radiolabelled Immune Targeting Peptide 2022-10-27 06:44
Telix Reports Third Quarter 2022 Financial Results 2022-10-20 06:09
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM 2022-10-18 06:43
Telix Partnership Expands GE Healthcare Immuno-Diagnostics Offering to the Global Clinical Research Market 2022-10-17 13:00
Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging 2022-10-17 07:25
Health Canada Approves Illuccix® for Prostate Cancer Imaging 2022-10-14 08:21
First Patient in New Zealand Dosed with Illuccix® - Telix's Prostate Cancer Imaging Agent 2022-09-30 02:30
Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate 2022-09-28 06:50
First Patient in Australia Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent 2022-09-28 05:00
First Patient Enrolled in ProstACT TARGET Study 2022-09-27 05:00
1 5 6 7 8 9